PharmGKB summary: pazopanib pathway, pharmacokinetics.
作者信息
Thorn Caroline F, Sharma Manish R, Altman Russ B, Klein Teri E
机构信息
Departments of aBiomedical Data Sciences bBiomedical Engineering cGenetics, Stanford University, Stanford, California dDepartment of Medicine, University of Chicago, Chicago, Illinois, USA.
出版信息
Pharmacogenet Genomics. 2017 Aug;27(8):307-312. doi: 10.1097/FPC.0000000000000292.
Abstract
摘要
相似文献
1
PharmGKB summary: pazopanib pathway, pharmacokinetics.药物基因组知识库摘要：帕唑帕尼作用途径、药代动力学。
Pharmacogenet Genomics. 2017 Aug;27(8):307-312. doi: 10.1097/FPC.0000000000000292.
2
Pazopanib: Clinical development of a potent anti-angiogenic drug.帕唑帕尼：一种强效抗血管生成药物的临床开发。
Crit Rev Oncol Hematol. 2011 Mar;77(3):163-71. doi: 10.1016/j.critrevonc.2010.02.012. Epub 2010 Apr 24.
3
PharmGKB summary: sorafenib pathways.PharmGKB总结：索拉非尼作用途径
Pharmacogenet Genomics. 2017 Jun;27(6):240-246. doi: 10.1097/FPC.0000000000000279.
4
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.帕唑帕尼和辛伐他汀同时使用会增加癌症患者转氨酶升高的风险。
Ann Oncol. 2012 Sep;23(9):2470-2471. doi: 10.1093/annonc/mds249.
5
Pazopanib for the treatment of metastatic renal cell carcinoma.帕唑帕尼治疗转移性肾细胞癌。
Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16.
6
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.帕唑帕尼，一种用于治疗肾细胞癌的强效口服小分子多靶点酪氨酸激酶抑制剂。
Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253.
7
Everolimus and pazopanib: two new drugs for renal cell cancer.依维莫司与帕唑帕尼：两种用于肾细胞癌的新药。
Med Lett Drugs Ther. 2010 May 3;52(1337):33-4.
8
Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?帕唑帕尼。肾癌：风险众多，但对患者有好处吗？
Prescrire Int. 2011 Mar;20(114):64-6.
9
Pazopanib in renal cell carcinoma.帕唑帕尼用于肾细胞癌
Clin Adv Hematol Oncol. 2010 Apr;8(4):232-3.
10
Pazopanib: therapeutic developments.帕唑帕尼：治疗进展。
Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493.
引用本文的文献
1
Elderberry interaction with pazopanib in a patient with soft‑tissue sarcoma: A case report and literature review.接骨木果与帕唑帕尼在一名软组织肉瘤患者中的相互作用：病例报告及文献综述
Mol Clin Oncol. 2024 Mar 20;20(5):36. doi: 10.3892/mco.2024.2734. eCollection 2024 May.
2
Genotyping in Clinical Practice: Ready for Implementation?临床实践中的基因分型：准备好实施了吗？
Front Genet. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021.
3
Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies.阿帕替尼相关甲状腺功能减退症在晚期恶性肿瘤患者中的临床观察
Exp Ther Med. 2020 Sep;20(3):1961-1966. doi: 10.3892/etm.2020.8937. Epub 2020 Jun 25.
4
Computational Methods for Identifying Similar Diseases.识别相似疾病的计算方法
Mol Ther Nucleic Acids. 2019 Dec 6;18:590-604. doi: 10.1016/j.omtn.2019.09.019. Epub 2019 Sep 28.
5
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma.帕唑帕尼与低脂肪餐（PALM）联合治疗晚期肾细胞癌。
Invest New Drugs. 2019 Apr;37(2):323-330. doi: 10.1007/s10637-018-0692-8. Epub 2018 Nov 5.
本文引用的文献
1
TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.酪氨酸激酶抑制剂联合疗法：通过抑制P糖蛋白和乳腺癌耐药蛋白介导的外排来增强达沙替尼摄取的策略。
Biopharm Drug Dispos. 2016 Oct;37(7):397-408. doi: 10.1002/bdd.2022. Epub 2016 Sep 13.
2
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.OCT2、MATE1 和 MATE2-K 的抑制可能是帕唑帕尼与顺铂药物相互作用的机制之一。
Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10.
3
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.晚期肾细胞癌一线治疗选用舒尼替尼或帕唑帕尼时的血管生成基因分型
Oncotarget. 2016 Jun 21;7(25):37599-37607. doi: 10.18632/oncotarget.9229.
4
Interleukin-8: A potent promoter of angiogenesis in gastric cancer.白细胞介素-8：胃癌血管生成的强效促进因子。
Oncol Lett. 2016 Feb;11(2):1043-1050. doi: 10.3892/ol.2015.4035. Epub 2015 Dec 15.
5
Association between Interleukin-8-251A/T polymorphism and gastric cancer susceptibility: a meta-analysis based on 5286 cases and 8000 controls.白细胞介素-8基因-251A/T多态性与胃癌易感性的关联：一项基于5286例病例和8000例对照的荟萃分析。
Int J Clin Exp Med. 2015 Dec 15;8(12):22393-402. eCollection 2015.
6
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?血压变化是否是帕唑帕尼和舒尼替尼治疗晚期/转移性肾细胞癌疗效的生物标志物？
Eur J Cancer. 2016 Jan;53:96-104. doi: 10.1016/j.ejca.2015.10.006. Epub 2015 Dec 15.
7
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.体外及癌症患者体内帕唑帕尼游离分数的测定表明白蛋白是主要结合位点。
Invest New Drugs. 2016 Feb;34(1):41-8. doi: 10.1007/s10637-015-0304-9. Epub 2015 Nov 16.
8
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.HLA - B*57:01使癌症患者易患帕唑帕尼相关肝损伤。
Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6.
9
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.帕唑帕尼或舒尼替尼治疗的肾细胞癌患者中白细胞介素8基因多态性与总生存期的关系
Br J Cancer. 2015 Mar 31;112(7):1190-8. doi: 10.1038/bjc.2015.64.
10
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.帕唑帕尼联合紫杉醇一线治疗晚期实体瘤的多中心 I 期研究。
Mol Cancer Ther. 2015 Feb;14(2):461-9. doi: 10.1158/1535-7163.MCT-14-0431. Epub 2014 Dec 10.
Zotero 插件